Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
everyone I talked to said if it closes at the high, we gonna get high
closing in on 200 million shares,
Should be a good day tomorrow as well
it's a kraken alright
Finally getting our run. Last time it ran from .002 to .018 it took 5 days (april this year). With today's warm up we should be in the pennies next week. At that point it's a hit or miss as to where to sell. Good luck everyone, I hope we all make a bundle.
There is a good chance this stock is going to come alive soon. Don't take it for granted, keep your eyes on the ticker symbol
Looks like the stock is starting to run, hopefully it gets back into the dollars this week, and never looks back.
Should be a green day today
Should be a green day today
Just a few short months ago, 6 months to be exact, MedMira only had 11 staff members. Today, the company has expanded to 54 people! It was truly amazing to see all of their employees who come from over 18 countries; there are 6 summer students and over 30 new immigrants.
GREAT WRITE UP FROM CANADIAN POLITICIAN
https://www.facebook.com/134268600446739/posts/808411506365775/?extid=gZpJa2yakqi1gWjA&d=n
great advice
Great facebook post by Canadian politician on MIR.v
MedMira has come out with a patent for #COVID19 that can detect if you have antibodies within minutes, and will show the results for days to follow (which is something that is not common with these types of tests).
Just a few short months ago, 6 months to be exact, MedMira only had 11 staff members.
Today, the company has expanded to 54 people! It was truly amazing to see all of their employees who come from over 18 countries; there are 6 summer students and over 30 new immigrants.
https://www.facebook.com/134268600446739/posts/808411506365775/?extid=gZpJa2yakqi1gWjA&d=n
Commercial sales to begin this month, stock undervalued
After 4 years as an R&D company, LXXGF finally starts commercial sales this month.
Set to be a market leader in veterinary diagnostics. 1 hour PCR test results for the LexaGene MiQLab vs. 4-5 business days for sending to outside lab.
COVID-19 testing turned out to be an unexpected bonus market. FDA EUA expected anytime from October to December 2020.
Shares are undervalued now relative to the large markets that LXXGF will enter and win.
https://seekingalpha.com/instablog/52496833-agni-research/5497965-lexagene-set-to-disrupt-veterinary-diagnostics-market
From the stockhouse bullboard
you're probably right
CLAYTRADER is a short clown. Stay away from his misleading posts
Claytrader works for the shorts. He gives the shorts a target price for the short traders to strive for. In this video he is pointing out to get to .85 cents. He never provides any upward prices always lower prices. GEVO is got them scared, the shorts have lost control with this stock.
CLAY works for the shorts, every one of his posts always elude to a dropping price. This latest video is showing it drop to .85. And since he is putting up so many posts on GEVO the shorts gotta be sh!tting themselves with this one. Expect the stock to climb back into the dollars, lots of contracts coming. The future is biofuel.
GOING TO KEEP GOING TILL AT LEAST $1.10
BIG BUY THIS WEEK, NEWS PENDING, PRICE OVERSOLD, CHARTS SAY REBOUND TO $1.10
stock looking good today
New German report puts a target price of $1.50 to $1.75 on MedMira short term and $3 a share long-term. Thanks in part to their latest news release on September 3.
https://www.wallstreet-online.de/nachricht/12902844-medmira-vorwaerts-lang-wars-ruhig-medmira-artikel-globe-newswire-facht-spekulation-an
FDA will approve before months end. From today's news release it can be seen our tests meet the FDA criteria. Good luck tomorrow
ALIFAX, Nova Scotia, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) reports findings to further emphasize the high sensitivity of REVEALCOVID-19™ Total Antibody Test 7 days post symptom onset as well as highlights the test’s zero cross-reactivity (i.e. no false positive results) with HIV positive samples.
https://ca.finance.yahoo.com/news/revealcovid-19-total-antibody-test-210000021.html
NEWS RELEASE SEPTEMBER 3, 2020 after market close:
https://ca.finance.yahoo.com/news/revealcovid-19-total-antibody-test-210000021.html
But they can sell during the review period.......I think tomorrow is going to be a good day for the stock, with the run to .38 a few days ago and today's close at the high
Think it is overdue, but I read that they are extra vigilant due to their past acceptance of less than adequate tests in the initial panic. Hermes Chan just posted on linked in (from stockhouse post):
The study reveals key finding about specific IgM, IgG1, and IgA1 antibody not only present in plasma or serum of almost all analyzed COVID-19 convalescent study subjects, most significantly is that these antibodies were also detected at exceptionally early stages of the infection (i.e., 7-8 days after disease onset).
This may set a new criteria and create great opportunity for serological tests used in screening convalescent plasma for the emergency therapeutic application critical for treating severe COVID-19 patients.
Accumulate as much of this stock as you can, antibody tests are an important component in fighting the pandemic. MedMira has the best antibody test, it is a total antibody test, nothing like it on the market.
some profit takers getting out of the way
Test Comparison
PCR-based tests look for the virus's genetic material in saliva or mucus samples to diagnose people who are currently infected with the novel coronavirus. PCR tests take 2 or more days for results.
Antigen tests can be used to screen individuals infected with the virus. These tests are less accurate than antibody and PCR tests, but they are great for detecting new cases. Antigen tests use a nasal or throat swab to detect viral proteins expressed on the outer surface of the coronavirus. Abbott Lab takes 15 minutes.
Antibody tests differ from antigen tests in that they detect the presence of proteins produced by the body in response to a previous infection. An antibody test measures antibodies in the blood to determine if you have had previous infection against the virus and have recovered. MedMira test takes up to 3 minutes.
From the yahoo messages board
shajandr is the correct spelling.....gonna be crying
he removed my post #47......obviously a nervous nellie when you point out the facts
shadandr moderates this board and has put up the stop sign on the header.............total short seller trying to protect his short position........also he removed my post where I stated the above.....big month coming
FNRC is going to come alive.
GLTA investors........September should be our month to shine
Going to be a busy week next week........stock is primed to bust through some keep technical indicators like the 50 DMA of .43 CDN. The last 3 days of trading have seen the volume pick up from 800,000 to 1,000,000 to 2,700,000 yesterday..............going bigger next week
In a short time, MedMira has developed an RVF®-based rapid test that detects total antibodies
to the SARS-CoV-2 virus, the causative agent of COVID-19, in human serum, plasma and
venipuncture whole blood.
Despite our financial constraints, MedMira, relying solely on our
dedicated team and stakeholders, was able to develop and validate the newest member of our
Reveal family, REVEALCOVID-19™ Total Antibody Test.
REVEALCOVID-19™ Total Antibody
Test is currently being manufactured under strict Good Manufacturing Practices (GMPs) at our
FDA-approved Halifax facility and in collaboration with our US-based partners.
Weekly
production shall, without a doubt, increase to the level required by our trusted distribution and
sales partners.
Since we announced the development of REVEALCOVID-19™ Total Antibody Test in April, we
have received many inquiries from our shareholders.
We have also become aware of a number
of inaccurate claims pertaining to MedMira. While it is not our policy to respond to market
rumors, I want to take this opportunity and provide additional clarity to our shareholders and
other stakeholders.
As a publicly listed company that strives for the highest quality of its
product, we take our disclosure obligations seriously and will only publish information that is
fully validated.
MedMira has submitted an Emergency Use Authorization (EUA) application to the United States
FDA.
At this time, REVEALCOVID-19™ Total Antibody Test application is under review.
During
the review, however, according to the FDA regulations, MedMira can legally sell and distribute
REVEALCOVID-19™ Total Antibody Test to the authorized laboratories in the United States.
MedMira plans to pursue these opportunities using its existing internal resources, which include
the recently made large product sale.
Following this successful agreement Company is able to
fulfill the needs of production as well as supply our trusted partners. Despite our difficult
financial position, in the past four years MedMira has raised its capital by means other than the
issue of new shares in order to preserve shareholder value.
At this point, MedMira is not
considering a capital raise and will not issue new shares and dilute our current shareholders.
We live in a world in which various information sources and opinions are available, however, not
all of them are trustworthy. MedMira’s management team is committed to providing timely and
transparent disclosure pertaining to our business and give reliable information to our
stakeholders.
With this letter we would like to re-emphasize MedMira Inc. due diligence in the
efforts to reassure our investors.
On behalf of MedMira’s team we thank you for your support and personally I am grateful to be a part of
this Company.
Yours sincerely,
Hermes Chan
Co-Founder and CEO
MedMira Inc.
HALIFAX, Nova Scotia, May 27, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test. Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million. The Company has received the down payment to initiate the production process.
MedMira is also pleased to announce that it has launched a new website, www.revealcovid19.com to provide the latest information about the product and the COVID-19 pandemic.
REVEALCOVID-19™ Total Antibody Test can detect antibodies to SARS-CoV-2, the virus that causes COVID-19, in the human serum, plasma and whole blood. Most serology tests detect only IgG and/or IgM antibodies, whereas REVEALCOVID-19™ Total Antibody Test is designed to detect all human immunoglobulins, including IgG, IgM and IgA. Because it measures total antibodies, the test can identify previous or present infection with the SARS-CoV-2 virus and helps to assess a person's immune response.
“Webb Diagnostic Technologies (www.webbdx.com) has built an extensive sales and marketing team who will certainly drive our business forward. We are pleased to secure this mutually beneficial exclusive partnership and bring this high-quality, portable antibody test to the U.S. market,” said Hermes Chan, CEO of MedMira. “As the demand for reliable SARS-CoV-2 antibody testing grows, this agreement is the first step in making our proven diagnostic platform available to more healthcare professionals throughout the United States.”
“High-quality antibody tests are an important tool in understanding a person's exposure to COVID-19 – critical information in limiting the spread of the virus and paving the way for people to return to normal activities and restart the U.S. economy,” said John P. Mayo, CEO, Webb Diagnostic Technologies. “REVEALCOVID-19™ fills a unique void in the growing testing landscape. We placed our first order and are excited to leverage MedMira’s technology to help our country move forward by enabling people to make safer, more informed choices about their health.”
The upside (risk-reward ratio) is huge for MedMira and I am really really confident they will receive FDA approval. Haven't sold a single share (quite the opposite). Here's why:
REVEALCOVID-19™ is MedMira's once in a lifetime opportunity to grow from startup into a serious diagnostics player. A product with global demand, which can be produced and distributed inexpensively with a (probably) solid profit-margin. Family Meile and the team won't let this opportunity pass by. (drive and enthusiasm)
Covid-19 getting even worse in the US and South America with roughly 40.000 new cases PER DAY (growing market)
REVEALCOVID-19™ Total Antibody Test is being currently manufactured at MedMira’s FDA-licensed (establishment license 3003595936) and ISO-certified Halifax facility
MedMira has completed registration process and affixed CE mark to its rapid REVEALCOVID-19™ total antibody test in May
MedMira is hiring like never before with several open positions to be filled urgently - "MedMira has ramped up its weekly production within a short period of time and has substantially increased its existing and trained work force in order to meet the increasing demand for its product."
One advantage MIR has over most of the market competition is that it identifies 3 Antibodies out of 5 (competitive advantage) - especially IgA. IgA detection show the highest sensitivity after 4-25 days
MedMira's technology, Rapid Vertical Flow, is patented - Simultaneous detection of multiple biomarkers on a single device
WebbDx , the exclusive US distributor, put real money on the table and ordered 3.5 Mio. USD worth of MedMira's (not-yet approved) REVEALCOVID-19™ product
WebbDx completed the process to do business with the U.S. Government (as of Aug 14th, check Cage code 8MTX2 at sam.gov)
WebbDx seems to plan export of products to Greece and Turkey (https://s3-us-west-2.amazonaws.com/cdn.ceo.ca/1fjfcnl-5A01CDBB-E35E-4605-9920-E0828BF337B3.png)
After allowing access to the US market under EUA notification, FDA now has to weed out a huge number of unusable test kits (removed 109 as of Aug 25th 2020). Only the best will we approved and Medmira is still under review!
WebbDx and MedMira have become quiet on social media and news in general - maybe they are just very careful and don't want to risk leaking any information (as it happened with the 3.5 Mio. agreement)
MedMira and WebbDx Management / Board members are accomplished experts in their field and have very strong connections and insights into the FDA approval process
MedMira Insiders (former early employees, directors, investors, board members) have not chosen to sell their stock / options
Same product setup already got FDA approval (only difference is the cartridge)
"Helping WebbDX navigate the FDA was something I was proud to do" - Congressman Aderholt (who will chair the House Appropriations subcommittees that govern the FDA and HHS)
"The FDA also stated in the letter that its current thinking on antibody tests was that they should have a minimum combined sensitivity of 90% and a minimum specificity of 95%. For tests that report specifically IgM and IgG, minimum sensitivity values of 90% and 70% for IgG and IgM respectively are called for." (Source: https://www.evaluate.com/vantage/articles/news/policy-and-regulation/fda-gets-aggressive-covid-19-antibody-tests)
No stock dilution in sight (according to Hermes Chan's letter)
Seriously, this company is no joke. Active for 27 years, trading publicly for 20 years. They waited years for this opportunity and will take full advantage of it. They are now at the right place, at the right time. Keep calm and stack shares (as they are really cheap now).
From stockhouse poster MrHODL
This stock will get FDA-EUA as it is one of the best tests for antibodies..............MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The product line of the company includes revealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products.
this is just getting started, buying at .0024 is ok as you aren't trying to sell at .0026.............more like .0126........on a stock like this the timing is more important.........and the time looks like run time.